@abbvie

Official global handle sharing the latest news about our company, science & people. Review our guidelines: https://xitter.cf/t.co/pvWvxd2VWF

 Global
AbbVie.com
Joined March 2012
  • Tweets8.9K
  • Following458
  • Followers79.3K
5.5KMedia
JUST IN: Today, the U.S. @FDA announced the approval of a subcutaneous induction regimen for one of our treatments for adults with moderately to severely active Crohn’s disease. Learn more: abbv.ie/f1c3e8
2
3
5
1,230
[Video description: On-screen text reads, “Immunology News.”]
312
NEWS: We announced topline results from our Phase 3 study in patients with #HidradenitisSuppurativa. Learn more: abbv.ie/fb8975
1
2
5
1,095
[Video description: On-screen text reads, “Immunology News.”]
1
234
AbbVie is now an Official Pharmaceutical Partner of @McLarenF1 AbbVie Race to Innovate is turning Constructors' Championship points into impact through donations to global charities that support those living with immune-mediated diseases. More: abbvie.com/mclarenf1 #McLarenF1
4
4
2
28
5,109
[Video description: Video detailing the launch of the AbbVie Race to Innovate campaign.]
2
399
This year's @myESMO marks our most expansive ESMO congress program to date, with data spanning multiple solid tumor types and stages of development across our #oncology portfolio. Read more: abbv.ie/4c99f1 #ESMO26
1
6
1,133
[Image description: Animation highlighting AbbVie's presence at ESMO 2026. On-screen text highlights 18 accepted abstracts spanning 7 solid tumor types and 7 assets across AbbVie's oncology portfolio.]
1
375
NEWS: We announced results from our Phase 2a study in patients with #CrohnsDisease. Learn more: abbv.ie/f19280
1
2
7
1,258
[Video description: On-screen text reads, "Immunology News."]
1
2
302
NEWS: AbbVie will share new data across our gastroenterology portfolio at #UEGWeek2026 in #CrohnsDisease and #UlcerativeColitis. Read more: abbv.ie/dfbc1e
1
1
6
1,652
[Video description: On-screen text reads, “Immunology News.”]
1
447
At #UEGWeek, we're presenting new research highlighting AbbVie’s ongoing dedication to advancing standards of care for people living with #IBD. Learn more about our work in #UlcerativeColitis and #CrohnsDisease: abbv.ie/026f21
2
1
8
1,836
[Video description: On-screen text reads: “At this year’s UEG Week, AbbVie will showcase the latest IBD data demonstrating our continued determination to advance the standards of care. Spanning innovative treatment approaches, real-world effectiveness, and...]
1
1
487
[“...long-term disease control, these findings underscore our dedication to helping patients achieve durable outcomes and improved quality of life.” Sofie Berg, Pharm.D., Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie.]
1
260
#DYK migraine is a highly prevalent disease globally? Migraine places a burden on individuals and families. Learn more about the burden of migraine and assess its impact with the Migraine Scoring System from @EMHAlliance: abbv.ie/02f152
1
2
941
[Video description: Migraine advocates and person living with migraine share their advice.]
361
JUST IN: New findings from our study in adults with #CrohnsDisease. Presented at #ACG2026, the results add to our growing body of evidence aimed at deepening our understanding of disease management and shaping the future of IBD care. Learn more: abbv.ie/658804
2
1
4
1,387
[Video description: On-screen text reads, “Immunology News.”]
497
This year at #ACG2026, we are presenting new long-term data in #IBD alongside emerging real-world evidence, reinforcing our portfolio across diverse and difficult-to-treat patient populations. Learn more: abbv.ie/1b7d6a
2
5
1,796
[Video description: Quote from Ryan DeMasi, M.D., VP, Global Medical Affairs, Immunology, AbbVie. On-screen text reads, “Our presence at ACG reflects AbbVie’s drive, as a leader in IBD, to provide what matters most to patients…”]
1
1
649
[“…therapies that perform over time and against the most complicated drivers of disease.”]
412
Load more